Suchen
Celularity Inc
CELUZur Watchlist hinzufügen
0.615USD
+0.017+2.86%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
17.74MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celularity Inc Unternehmen
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Inc Informationen
BörsenkürzelCELU
Name des UnternehmensCelularity Inc
IPO-datumMay 23, 2019
CEOHariri (Robert J)
Anzahl der mitarbeiter123
WertpapierartOrdinary Share
GeschäftsjahresendeMay 23
Addresse170 Park Ave
StadtFLORHAM PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07932
Telefon19087682170
Websitehttps://celularity.com/
BörsenkürzelCELU
IPO-datumMay 23, 2019
CEOHariri (Robert J)
Führungskräfte von Celularity Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Celularity Inc?
Die fünf größten Anteilseigner von Celularity Inc sind: Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Wie viele Institutionen halten Anteile an Celularity Inc (CELU)?
Mit Stand vom 2026Q1 halten 64 Institutionen Anteile an Celularity Inc, mit einem Gesamtmarktwert von etwa 3.75M, was 12.95% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -258480.00 gestiegen.